Crispr Therapeutics AG vs iShares MBS ETF — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while iShares MBS ETF trades at $92.85. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| CRSP | MBB | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | — |
52-Week High | $76.78 | $96.91 |
52-Week Low | $44.34 | $92.72 |
Enterprise Value | $3.65B | — |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →